Last reviewed · How we verify
NCT06738810: STEATOGWAD
: Identification of Non-alcoholic Steato-hepatitis Cases in a Sample of Type 2 Diabetes Patients, with a Disruption of the Liver Function Tests, At the Pointe-à-Pitre University Hospital
NA trial testing Fibrotest-actitest/NASHtest in Non-alcoholic Steato-hepatitis in 103 participants. Completed in 1 February 2022.
1 February 2022
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de la Guadeloupe |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 103 |
| Start date | 21 June 2018 |
| Primary completion | 1 February 2022 |
| Estimated completion | 1 February 2022 |
| Sites | 1 location across Guadeloupe |
Drugs / interventions tested
- Fibrotest-actitest/NASHtest
Conditions studied
- Non-alcoholic Steato-hepatitis — all drugs for Non-alcoholic Steato-hepatitis →
Sponsor
Centre Hospitalier Universitaire de la Guadeloupe
Who can join
18 and older, any sex, with Non-alcoholic Steato-hepatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Non-alcoholic steatohepatitis (NASH) develops on insulin resistance, especially in patients with carbohydrate tolerance. NASH may progress to more extensive fibrosis, including cirrhosis, but also to HCC with or without cirrhosis in 10 to 20% of cases. The main objective of our research is to identify the prevalence of NASH in a sample of 100 patients with type 2 diabetes mellitus (T2DM), consulting in the PAP hospital and having a liver function disorder
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06738810
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier Universitaire de la Guadeloupe trials
Trials by the same sponsor.
- NCT07266376 — Validation of a VOICE MAnagement Program in Schizophrenia VVoice MAPS · NA · not yet recruiting
- NCT07292454 — Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe · not yet recruiting
- NCT07265986 — Comparison Between a Robotic Tele-echo-cardiography Technique and a Standard Echocardiography in the Management of Heart · NA · recruiting
- NCT07330830 — Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (A · recruiting
- NCT07233447 — Prevalence of H. Pylori in Stomach Cancers in the West Indies · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06738810 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de la Guadeloupe
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06738810.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing